GR3033630T3 - Gene expression elements and the production of chimeric mouse-human antibodies. - Google Patents
Gene expression elements and the production of chimeric mouse-human antibodies.Info
- Publication number
- GR3033630T3 GR3033630T3 GR20000401317T GR20000401317T GR3033630T3 GR 3033630 T3 GR3033630 T3 GR 3033630T3 GR 20000401317 T GR20000401317 T GR 20000401317T GR 20000401317 T GR20000401317 T GR 20000401317T GR 3033630 T3 GR3033630 T3 GR 3033630T3
- Authority
- GR
- Greece
- Prior art keywords
- production
- gene expression
- expression elements
- human antibodies
- chimeric mouse
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24062488A | 1988-09-06 | 1988-09-06 | |
US24174488A | 1988-09-08 | 1988-09-08 | |
US24373988A | 1988-09-13 | 1988-09-13 | |
US25300288A | 1988-10-04 | 1988-10-04 | |
US36764189A | 1989-06-19 | 1989-06-19 | |
US38276889A | 1989-07-21 | 1989-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
GR3033630T3 true GR3033630T3 (en) | 2000-10-31 |
Family
ID=27559300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR20000401317T GR3033630T3 (en) | 1988-09-06 | 2000-06-07 | Gene expression elements and the production of chimeric mouse-human antibodies. |
Country Status (9)
Country | Link |
---|---|
US (1) | US6461824B1 (el) |
EP (2) | EP0967277A3 (el) |
AT (1) | ATE190355T1 (el) |
AU (1) | AU643189B2 (el) |
CA (1) | CA1341351C (el) |
DE (1) | DE68929167T2 (el) |
ES (1) | ES2146572T3 (el) |
GR (1) | GR3033630T3 (el) |
WO (1) | WO1990002569A1 (el) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5576184A (en) * | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
ATE190355T1 (de) | 1988-09-06 | 2000-03-15 | Xoma Corp | Genexpressions-elemente und herstellung von chimären maus-mensch-antikörpern |
IL89490A0 (en) * | 1988-11-17 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against metal chelates |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US6291159B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
EP0404003A3 (en) * | 1989-06-19 | 1991-10-16 | Xoma Corporation | Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen |
US5580774A (en) * | 1989-07-31 | 1996-12-03 | Eli Lilly And Company | Chimeric antibodies directed against a human glycoprotein antigen |
AU662311B2 (en) * | 1991-02-05 | 1995-08-31 | Novartis Ag | Recombinant antibodies specific for a growth factor receptor |
US20050196400A1 (en) * | 1991-05-06 | 2005-09-08 | Xoma Technology Ltd. | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
US5621083A (en) | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
US6146850A (en) | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
US5837491A (en) * | 1991-11-04 | 1998-11-17 | Xoma Corporation | Polynucleotides encoding gelonin sequences |
US6037121A (en) * | 1995-12-08 | 2000-03-14 | University Technologies International Inc. | DNA sequence encoding a tumor suppressor gene |
US6117633A (en) | 1995-12-08 | 2000-09-12 | University Technologies International Inc. | DNA sequence encoding the tumor suppressor gene ING1 |
US6747133B1 (en) | 1995-12-08 | 2004-06-08 | University Technologies International Inc. | Antibodies against the tumor suppressor gene ING1 |
US6143522A (en) * | 1995-12-08 | 2000-11-07 | University Technologies International, Inc. | Methods of modulating apoptosis |
US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
JP2005522192A (ja) | 2001-07-19 | 2005-07-28 | パーラン セラピューティクス, インコーポレイテッド | マルチマータンパク質およびマルチマータンパク質を作製および使用する方法 |
WO2003074705A1 (fr) * | 2002-03-01 | 2003-09-12 | Japan Envirochemicals, Ltd. | Proteines capables de se fixer sur des hormones environnementales et procede permettant de les produire |
US20050009097A1 (en) * | 2003-03-31 | 2005-01-13 | Better Marc D. | Human engineered antibodies to Ep-CAM |
US20050138692A1 (en) * | 2003-06-02 | 2005-06-23 | Biotechnology Foundation, Inc. | Production of cancer-specific antibodies in plants |
WO2006012414A2 (en) * | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Novel polyadenylation signal for use in expression vectors |
US8211648B2 (en) | 2005-07-22 | 2012-07-03 | Kalobios Pharmaceuticals, Inc. | Secretion of antibodies without signal peptides from bacteria |
PE20140196A1 (es) * | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
ES2728095T3 (es) | 2008-02-01 | 2019-10-22 | Her Majesty The Queen In Right Of Canada As Represented By The Mini Of Health | Anticuerpos monoclonales para los virus del Ebola y Marburgo |
RU2724663C2 (ru) | 2010-02-08 | 2020-06-25 | Ридженерон Фармасьютикалз, Инк. | Мышь с общей легкой цепью |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
MY172718A (en) | 2011-08-05 | 2019-12-11 | Regeneron Pharma | Humanized universal light chain mice |
JP2015517511A (ja) | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cd37抗体とice(イフォスファミド、カルボプラチン、エトポシド)の併用 |
JP2015525071A (ja) * | 2012-06-05 | 2015-09-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 共通の軽鎖を用いて完全ヒト型二重特異性抗体を作製するための方法 |
KR102601491B1 (ko) | 2014-03-21 | 2023-11-13 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
CN107438622A (zh) | 2015-03-19 | 2017-12-05 | 瑞泽恩制药公司 | 选择结合抗原的轻链可变区的非人动物 |
WO2018152452A1 (en) | 2017-02-17 | 2018-08-23 | Mapp Biopharmaceutical, Inc. | Monoclonal antibodies and cocktails for treatment of ebola infections |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4612282A (en) * | 1981-12-15 | 1986-09-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Monoclonal antibodies reactive with human breast cancer |
US4818709A (en) | 1983-01-21 | 1989-04-04 | Primus Frederick J | CEA-family antigens, Anti-CEA antibodies and CEA immunoassay |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS60224492A (ja) * | 1984-04-24 | 1985-11-08 | Yuu Honshiyo | 異種遺伝子の結合法 |
EP0173494A3 (en) * | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
JPS61167699A (ja) * | 1985-01-19 | 1986-07-29 | Green Cross Corp:The | モノクロ−ナル抗体 |
AU606320B2 (en) * | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
CA1341281C (en) | 1986-07-09 | 2001-08-07 | Hubert J.P. Schoemaker | Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen |
DK175363B1 (da) * | 1986-09-12 | 2004-09-13 | Genentech Inc | Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren |
IL84285A (en) * | 1986-10-27 | 1993-03-15 | Int Genetic Engineering | Chimeric antibody with specificity to human tumor antigen |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US4816282A (en) * | 1987-09-30 | 1989-03-28 | Lonza Inc. | Moisture-stabilized foods having improved shelf life |
CA1340221C (en) | 1988-01-29 | 1998-12-15 | Thomas Frank Bumol | Vectors, compounds and method for expression of a human adenocarcinoma antigen |
US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
ATE190355T1 (de) | 1988-09-06 | 2000-03-15 | Xoma Corp | Genexpressions-elemente und herstellung von chimären maus-mensch-antikörpern |
US5576184A (en) | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
JPH04501266A (ja) | 1988-10-12 | 1992-03-05 | セントコアー,インコーポレーテッド | ヨード―125で標識された放射線療法用接合体 |
WO1993008298A1 (en) | 1991-10-18 | 1993-04-29 | The Wistar Institute Of Anatomy And Biology | Soluble variants of type i membrane proteins, and methods of using them |
-
1989
- 1989-09-06 AT AT89309048T patent/ATE190355T1/de not_active IP Right Cessation
- 1989-09-06 EP EP99202598A patent/EP0967277A3/en not_active Withdrawn
- 1989-09-06 EP EP89309048A patent/EP0364096B1/en not_active Expired - Lifetime
- 1989-09-06 CA CA000610388A patent/CA1341351C/en not_active Expired - Fee Related
- 1989-09-06 WO PCT/US1989/003852 patent/WO1990002569A1/en unknown
- 1989-09-06 DE DE68929167T patent/DE68929167T2/de not_active Expired - Fee Related
- 1989-09-06 AU AU44021/89A patent/AU643189B2/en not_active Ceased
- 1989-09-06 ES ES89309048T patent/ES2146572T3/es not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/467,142 patent/US6461824B1/en not_active Expired - Fee Related
-
2000
- 2000-06-07 GR GR20000401317T patent/GR3033630T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0364096A2 (en) | 1990-04-18 |
WO1990002569A1 (en) | 1990-03-22 |
ATE190355T1 (de) | 2000-03-15 |
CA1341351C (en) | 2002-03-26 |
EP0364096A3 (en) | 1992-08-05 |
AU4402189A (en) | 1990-04-02 |
EP0967277A2 (en) | 1999-12-29 |
DE68929167T2 (de) | 2000-11-16 |
EP0967277A3 (en) | 2003-10-15 |
AU643189B2 (en) | 1993-11-11 |
DE68929167D1 (de) | 2000-04-13 |
ES2146572T3 (es) | 2000-08-16 |
US6461824B1 (en) | 2002-10-08 |
EP0364096B1 (en) | 2000-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR3033630T3 (en) | Gene expression elements and the production of chimeric mouse-human antibodies. | |
ZA878044B (en) | Chimeric antibody with specificity to human tumor antigen | |
EP0274394A3 (en) | Chimeric antibody with specificity to human b cell surface antigen | |
DK69890A (da) | Monoklonale antistoffer, der er reaktive med cachetin | |
GR78180B (el) | ||
PL266680A1 (en) | Method of obtaining il-6 and of its application | |
DE3581578D1 (de) | Antikoerper, herstellung und verwendung. | |
DE3581400D1 (de) | Maus/mensch-hybridoma mit erzeugung von antiviralen menschlichen antikoerpern, deren herstellung und antivirale menschliche monoklonale antikoerper. | |
EP0404003A3 (en) | Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen | |
AU2456888A (en) | Monoclonal antibodies specific for HIV and hybridomas for their production | |
HU9800744D0 (en) | Anti-fas antibodies | |
EP0160486A3 (en) | Monoclonal antibodies | |
ES2061566T3 (es) | Anticuerpos monoclonales contra la proteina e7 del papilomavirus humano tipo 16, procedimiento para su preparacion, asi como su empleo. | |
EP0166458A3 (en) | Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells | |
EP0272113A3 (en) | Anti-human cancer monoclonal antibodies | |
SU572590A1 (ru) | Струйный усилитель | |
AU2687992A (en) | Sf-25 antibodies, especially chimeric antibodies, with specificity for the human tumor sf-25 antigen, methods for their production, and uses thereof | |
HUT48677A (en) | Process for producing mouse hybridoma lym-2 and diagnostic antibody therefrom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ML | Lapse due to non-payment of fees |